Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

Next Previous
Trial Profile

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Aspirin
  • Indications Essential thrombocythaemia; Polycythaemia vera; Venous thrombosis
  • Focus Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 08 Dec 2020 Results of pooled analysis (of data from MPN-RC 111 and MPN-RC 112 studies) assessing the Symptom burden and quality of life in high-risk essential Thrombocythemia and Polycythemia Vera patients presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 Results assessing activity of pegylated interferon alfa-2a (PEG) in two trials (MPD-RC 111; NCT01259817 and MPD-RC 112; NCT01258856) released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results assessing MPN symptom impact and quality of life, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top